La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Avecho Biotechnology Résultats passés
Passé contrôle des critères 0/6
Avecho Biotechnology's earnings have been declining at an average annual rate of -19.8%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been declining at an average rate of 36.5% per year.
Informations clés
-19.8%
Taux de croissance des bénéfices
-14.4%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 31.2% |
Taux de croissance des recettes | -36.5% |
Rendement des fonds propres | -53.9% |
Marge nette | -725.7% |
Dernière mise à jour des bénéfices | 31 Dec 2023 |
Mises à jour récentes des performances passées
Recent updates
Companies Like Avecho Biotechnology (ASX:AVE) Are In A Position To Invest In Growth
Jan 13Here's Why We're Watching Avecho Biotechnology's (ASX:AVE) Cash Burn Situation
May 31Avecho Biotechnology (ASX:AVE) Is In A Good Position To Deliver On Growth Plans
Nov 04We're Hopeful That Avecho Biotechnology (ASX:AVE) Will Use Its Cash Wisely
Jul 14We Think Avecho Biotechnology (ASX:AVE) Can Afford To Drive Business Growth
Mar 23We're Not Very Worried About Avecho Biotechnology's (ASX:AVE) Cash Burn Rate
Dec 08Ventilation des recettes et des dépenses
Comment Avecho Biotechnology gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
31 Dec 23 | 0 | -3 | 2 | 1 |
30 Sep 23 | 1 | -4 | 3 | 1 |
30 Jun 23 | 1 | -4 | 3 | 1 |
31 Mar 23 | 1 | -3 | 3 | 1 |
31 Dec 22 | 1 | -2 | 2 | 1 |
30 Sep 22 | 1 | -2 | 2 | 1 |
30 Jun 22 | 1 | -2 | 3 | 1 |
31 Mar 22 | 1 | -3 | 3 | 1 |
31 Dec 21 | 1 | -3 | 3 | 1 |
30 Sep 21 | 1 | -3 | 3 | 1 |
30 Jun 21 | 0 | -3 | 3 | 1 |
31 Mar 21 | 0 | -3 | 3 | 0 |
31 Dec 20 | 0 | -3 | 3 | 0 |
30 Sep 20 | 0 | -2 | 2 | 0 |
30 Jun 20 | 0 | -2 | 2 | 0 |
31 Mar 20 | 2 | -1 | 2 | 0 |
31 Dec 19 | 4 | 1 | 2 | 0 |
30 Sep 19 | 4 | 1 | 2 | 0 |
30 Jun 19 | 5 | 0 | 3 | 0 |
31 Mar 19 | 3 | -2 | 3 | 0 |
31 Dec 18 | 1 | -4 | 4 | 0 |
30 Jun 18 | 1 | -6 | 6 | 1 |
31 Mar 18 | 1 | -7 | 7 | 1 |
31 Dec 17 | 1 | -9 | 8 | 1 |
30 Jun 17 | 1 | -16 | 8 | 1 |
31 Mar 17 | 1 | -17 | 8 | 1 |
31 Dec 16 | 2 | -17 | 8 | 2 |
30 Sep 16 | 2 | -17 | 9 | 2 |
30 Jun 16 | 3 | -17 | 9 | 2 |
31 Mar 16 | 2 | -18 | 9 | 2 |
31 Dec 15 | 2 | -20 | 9 | 2 |
30 Sep 15 | 2 | -17 | 8 | 2 |
30 Jun 15 | 3 | -14 | 7 | 3 |
31 Mar 15 | 2 | -10 | 6 | 3 |
31 Dec 14 | 2 | -7 | 6 | 3 |
30 Jun 14 | 1 | -7 | 6 | 3 |
31 Mar 14 | 1 | -9 | 7 | 3 |
31 Dec 13 | 1 | -11 | 7 | 4 |
30 Sep 13 | 1 | -12 | 9 | 3 |
Des revenus de qualité: AVE is currently unprofitable.
Augmentation de la marge bénéficiaire: AVE is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AVE is unprofitable, and losses have increased over the past 5 years at a rate of 19.8% per year.
Accélération de la croissance: Unable to compare AVE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: AVE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).
Rendement des fonds propres
ROE élevé: AVE has a negative Return on Equity (-53.88%), as it is currently unprofitable.